6929 Stock Overview
An investment holding company, researches, develops, manufactures, trades in, sells, and markets medical devices/instruments used for the treatment of coronary and peripheral vascular diseases in Japan, Europe, the Middle East, Africa, the Asia Pacific, the People’s Republic of China, and the United States.
Snowflake Score | |
---|---|
Valuation | 6/6 |
Future Growth | 1/6 |
Past Performance | 4/6 |
Financial Health | 5/6 |
Dividends | 2/6 |
Rewards
Risk Analysis
OrbusNeich Medical Group Holdings Limited Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | HK$3.22 |
52 Week High | HK$9.52 |
52 Week Low | HK$3.00 |
Beta | 0 |
11 Month Change | -19.30% |
3 Month Change | -21.65% |
1 Year Change | -62.95% |
33 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -64.81% |
Recent News & Updates
Some Confidence Is Lacking In OrbusNeich Medical Group Holdings Limited (HKG:6929) As Shares Slide 28%
Jul 19OrbusNeich Medical Group Holdings Limited (HKG:6929) Shares Could Be 39% Below Their Intrinsic Value Estimate
Jul 03Is OrbusNeich Medical Group Holdings (HKG:6929) A Risky Investment?
May 28Recent updates
Some Confidence Is Lacking In OrbusNeich Medical Group Holdings Limited (HKG:6929) As Shares Slide 28%
Jul 19OrbusNeich Medical Group Holdings Limited (HKG:6929) Shares Could Be 39% Below Their Intrinsic Value Estimate
Jul 03Is OrbusNeich Medical Group Holdings (HKG:6929) A Risky Investment?
May 28Optimistic Investors Push OrbusNeich Medical Group Holdings Limited (HKG:6929) Shares Up 27% But Growth Is Lacking
May 06OrbusNeich Medical Group Holdings' (HKG:6929) Earnings Are Weaker Than They Seem
Apr 25Some Confidence Is Lacking In OrbusNeich Medical Group Holdings Limited (HKG:6929) As Shares Slide 26%
Mar 13Returns At OrbusNeich Medical Group Holdings (HKG:6929) Appear To Be Weighed Down
Feb 04A Look At The Intrinsic Value Of OrbusNeich Medical Group Holdings Limited (HKG:6929)
Oct 20Some OrbusNeich Medical Group Holdings Limited (HKG:6929) Shareholders Look For Exit As Shares Take 28% Pounding
Jun 01Shareholder Returns
6929 | HK Medical Equipment | HK Market | |
---|---|---|---|
7D | -0.6% | 1.2% | -0.02% |
1Y | -62.9% | -49.3% | -5.2% |
Return vs Industry: 6929 underperformed the Hong Kong Medical Equipment industry which returned -49.3% over the past year.
Return vs Market: 6929 underperformed the Hong Kong Market which returned -5.2% over the past year.
Price Volatility
6929 volatility | |
---|---|
6929 Average Weekly Movement | 8.1% |
Medical Equipment Industry Average Movement | 7.5% |
Market Average Movement | 6.5% |
10% most volatile stocks in HK Market | 13.8% |
10% least volatile stocks in HK Market | 3.6% |
Stable Share Price: 6929's share price has been volatile over the past 3 months.
Volatility Over Time: 6929's weekly volatility (8%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2001 | 1,249 | David Chien | orbusneich.com |
OrbusNeich Medical Group Holdings Limited, an investment holding company, researches, develops, manufactures, trades in, sells, and markets medical devices/instruments used for the treatment of coronary and peripheral vascular diseases in Japan, Europe, the Middle East, Africa, the Asia Pacific, the People’s Republic of China, and the United States. The company offers semi-compliant balloons and scoring balloons for pre-dilatation and lesion preparation, stents for implantation, non-compliant balloons for post-dilatation, and specialty catheters, as well as sirolimus-eluting coronary stents, peripheral self-expandable stents, and paclitaxel-coated PTCA and PTA balloons. Its product portfolio covers various treatment processes in percutaneous coronary intervention (PCI) and percutaneous transluminal angioplasty (PTA) procedures.
OrbusNeich Medical Group Holdings Limited Fundamentals Summary
6929 fundamental statistics | |
---|---|
Market cap | HK$2.66b |
Earnings (TTM) | HK$351.84m |
Revenue (TTM) | HK$1.20b |
7.6x
P/E Ratio2.2x
P/S RatioIs 6929 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
6929 income statement (TTM) | |
---|---|
Revenue | US$153.87m |
Cost of Revenue | US$47.37m |
Gross Profit | US$106.50m |
Other Expenses | US$61.43m |
Earnings | US$45.07m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | 0.054 |
Gross Margin | 69.22% |
Net Profit Margin | 29.29% |
Debt/Equity Ratio | 1.1% |
How did 6929 perform over the long term?
See historical performance and comparison